SCHEMBL839860

SCHEMBL839860

Cc1ccc(NC(=O)C(C)O)nc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.66
MAPT P10636 3/20 0.66
KDM4E B2RXH2 3/20 0.56
NPC1 O15118 11/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
ALDH1A1 P00352 3/20 0.51
HPGD P15428 1/20 0.51
ATM Q13315 1/20 0.51
GAA P10253 2/20 0.50
TP53 P04637 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
GLA P06280 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PKM P14618 1/20 0.50
HTT P42858 1/20 0.49
XIAP P98170 1/20 0.48
BIRC2 Q13490 1/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9891790 0.88 RAB9A (0.68) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL839227 0.87 RAB9A (0.62) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL839347 0.87 RAB9A (0.62) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL839228 0.87 RAB9A (0.62) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL13086264 0.85 RAB9A (0.60) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL15986869 0.85 XIAP (0.64) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL21401471 0.85 RAB9A (0.64) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL838394 0.82 RAB9A (0.60) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL838669 0.82 RAB9A (0.60) RAB9AMAPTKDM4ENPC1SMN1; SMN2
SCHEMBL17409810 0.82 RAB9A (0.60) RAB9AMAPTKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 RAB9A 3239/4885MAPT 3944/4885KDM4E 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.